Association of serum and vitreous concentrations of osteoprotegerin with diabetic retinopathy

Annals of Clinical Biochemistry

Volumn 52, Issue 2, 2015, Pages 232-236

  Yu, Gehua ^a   Ji, Xiaoyan ^b   Jin, Ji ^b   Bu, Shuyang ^b  

^a SOOCHOW UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

angiogenesis; cytokines; diabetes; diabetic retinopathy; Osteoprotegerin; peptide hormones

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; TNFRSF11B PROTEIN, HUMAN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SERUM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VITREOUS BODY; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHEMISTRY; CHINA; COMPLICATION; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; UNIVERSITY HOSPITAL; UPREGULATION;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; CHINA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; SEVERITY OF ILLNESS INDEX; UP-REGULATION; VITREOUS BODY;

EID: 84924761071     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563214533669     Document Type: Article

References (22)

1. Siemianowicz K,Gminski J,Telega A, et al.Blood antioxidant parameters in patients with diabetic retinopathy.Int J Mol Med. 2004;14:433-437
2. Negi A,Vernon SA.An overview of the eye in diabetes.J R Soc Med. 2003;96:266-272
3. Zhou J,Wang S,Xia X.Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy.Curr Eye Res. 2012;37:416-420
4. Cross SS,Yang Z,Brown NJ, et al.Osteoprotegerin (OPG) – a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?.Int J Cancer. 2006;118:1901-1908
5. Hofbauer LC,Khosla S,Dunstan CR, et al.The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.J Bone Miner Res. 2000;15:2-12
6. Bucay N,Sarosi I,Dunstan CR, et al.osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.Genes Dev. 1998;12:1260-1268
7. McGonigle JS,Giachelli CM,Scatena M.Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.Angiogenesis. 2009;12:35-46
8. Simonet WS,Lacey DL,Dunstan CR, et al.Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.Cell. 1997;89:309-319
9. Kobayashi-Sakamoto M,Isogai E,Holen I.Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells.Eur J Haematol. 2010;85:26-35
10. Secchiero P,Corallini F,Pandolfi A, et al.An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.Am J Pathol. 2006;169:2236-2244
11. Xiang GD,Xu L,Zhao LS, et al.The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes.Diabetes. 2006;55:2126-2131
12. Xiang GD,Sun HL,Zhao LS.Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients.Diabetes Res Clin Pract. 2007;76:199-206
13. Davenport C,Ashley DT,O'Sullivan EP, et al.Identifying coronary artery disease in men with type 2 diabetes: osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk.J Hypertens. 2011;29:2469-2475
14. Guzel S,Seven A,Kocaoglu A, et al.Osteoprotegerin, leptin and IL-6: association with silent myocardial ischemia in type 2 diabetes mellitus.Diabetes Vasc Dis Res. 2013;10:25-31
15. Poulsen MK,Nybo M,Dahl J, et al.Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus.Cardiovasc Diabetol. 2011;10:76-76
16. Terekeci HM,Senol MG,Top C, et al.Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy.Exp Clin Endocrinol Diabetes. 2009;117:119-123
17. Nybo M,Poulsen MK,Grauslund J, et al.Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients.Diabet Med. 2010;27:289-294
18. Xiang GD,Pu JH,Zhao LS, et al.Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes.Diabet Med. 2009;26:397-403
19. Knudsen ST,Foss CH,Poulsen PL, et al.Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications.Eur J Endocrinol. 2003;149:39-42
20. Benslimane-Ahmim Z,Heymann D,Dizier B, et al.Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties.J Thromb Haemost. 2011;9:834-843
21. Benslimane-Ahmim Z,Poirier F,Delomenie C, et al.Mechanistic study of the proangiogenic effect of osteoprotegerin.Angiogenesis. 2013;16:575-593
22. Mankoč Ramuš S,Kumše T,Globočnik Petrovič M, et al.SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes.Biomed Res Int. 2013;2013:364073-364073